MEchanism-Resolved Inference of Trial outcomes (MERIT), a model that predicts trial outcomes from molecular and disease features without using information on similar-compound success, is developed.
Abstract
Drug development depends on efficacy and safety, but many trial-outcome prediction models incorporate trial design, prior development history or compound identity, enabling compound memorization and inflating apparent performance. We developed MEchanism-Resolved Inference of Trial outcomes (MERIT), a model that predicts trial outcomes from molecular and disease features without using information on similar-compound success. MERIT integrates the disease and drug of interest with large-scale drug-protein, protein-metabolite and immune interaction maps to link a drug’s intended and potential off-target effects to tissue-specific efficacy and safety. Across 753 small-molecule drugs and 3,133 trials, MERIT achieved a best-in-class overall AUROC of 0.770 (0.765 for efficacy and 0.784 for safety). MERIT also recovered the eventual approved indications for 83% of failed drugs. Finally, we registered locked, outcome-blind predictions for 55 drug-indication pairs in ongoing Phase III trials, establishing a prospective evaluation cohort.
Clinical drug development suffers from high rates of toxicity-related failure despite the use of compound-centric preclinical safety screening, with approximately one-third of all clinical failures attributable to safety concerns. An ability to prioritize early-stage drug development programs toward those with a lower...
Jordan Breffle, Alex Jones, S. Ghiassian· Scientific Reports· 0 citations
Numerous drug candidates showed great promise in experimental and preclinical investigations but failed in clinical trials. One cause to this problem may be nonspecific drug biodistribution, leading to adverse effects in healthy organs. Drug delivery technologies are developed to overcome this exact problem by naviga...
Estimating the probability of success (POS) of clinical trials remains a major challenge in drug development. Legacy forecasting approaches in the biopharmaceutical industry rely on historical averages stratified by development phase and therapy area, which obscures the contribution of trial design to clinical outcom...
Robert Howard, Beau Bush, Joseph Edelmann et al.· Scientific Reports· 0 citations
Traditional drug development suffers from high costs, low success rates, and patient response variability. Precision drug discovery seeks to overcome these limitations by targeting specific genetic and molecular mechanisms but faces challenges in integrating cross-scale, multimodal biomedical data. Recent advances in a...
This scoping review investigates the current state of PK property prediction of small molecules in drug discovery using machine learning methods and a combination of machine learning and mechanistic models and proposes leveraging the pattern recognition capabilities of deep learning models in conjunction with the biolo...
Lucille Tomin, Vida Bodaghi-Namileh, D. G. Schwartz et al.· Journal of Chemical Informat...· 0 citations
Drug–drug interactions (DDIs) are a major source of preventable medication-related harm, but the evidence used to anticipate them spans molecular structure, pharmacology, biomedical text, knowledge graphs, and longitudinal clinical records. Computational studies often treat distinct targets as a single benchmark, even...
Jing-Xiang Yang· Computers and artificial int...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
